AKTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AKTS is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some bullish analyst support and strong revenue growth, but the current technical trend is weak, no proprietary buy signal is active, options sentiment is neutral-to-bullish but not strong enough to override the chart, and the company is still losing money. Based on the data, the best direct call is to hold off rather than buy now.
The short-term trend is mixed to bearish. MACD histogram is negative and expanding, which points to weakening momentum. RSI_6 at 41.8 is neutral but leaning weak, not indicating an attractive momentum entry. Moving averages are converging, suggesting an inflection point is possible, but it is not a confirmed uptrend. Price at 18.84 is below the pivot at 20.138 and only slightly above S1 at 18.19, so the stock is near support but not showing strong breakout behavior. The modeled candlestick outlook is also weak over the next month, with an expected -7.23% move.
The company posted very strong year-over-year revenue growth in Q4
The miniprotein radiopharmaceutical platform is viewed positively and could address a large market opportunity. The stock is near technical support, which may attract value-oriented buyers.
The company remains unprofitable, with a meaningful net loss and negative EPS in the latest quarter. Technical momentum is deteriorating, with a negative expanding MACD histogram. There is no AI Stock Picker signal and no recent SwingMax signal. Hedge funds and insiders are neutral, so there is no notable institutional or insider accumulation. News flow is not directly about AKTS and does not provide a fresh stock-specific catalyst. The modeled next-month trend is negative.
In Q4 2025, AKTS showed strong top-line improvement, with revenue rising 100.43% year over year to 1.87 million. However, profitability remains weak: net income was -15.138 million and EPS was -0.30, even though both improved year over year. Gross margin was reported at 100, but the business is still in a loss-making stage. For a beginner long-term investor, the growth is promising but the financial profile is still speculative.
Analyst sentiment has improved recently. On 2026-03-09, H.C. Wainwright initiated coverage with a Buy and $30 target, then on 2026-03-31 raised the target to $33 from $30 while keeping Buy. On 2026-04-29, William Blair initiated Outperform, citing potential to become a radiopharmaceuticals leader. The Wall Street pros view is clearly positive overall, but the stock price has not yet confirmed that optimism.
